Avicidin

An investigational radioimmunotherapeutic agent for treating advanced therapeutically refractive cancers of the colon, ovarian and prostate, which delivers high-dose RT to metastatic tumours, while minimising exposure of normal tissues, especially bone marrow. Avicidin was discontinued in phase-II trials due to a high incidence of unacceptable diarrhea, which was atributed to cross-reactivity of the Avicidin anti-Epcam antibody with the intestine.

References in periodicals archive

One of these is a full-length IgG specific for EpCAM (a marker of colorectal cancer) developed as the drug Avicidin by NeoRx and Monsanto.

Plantibodies

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.